ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
A Comparative Study of Porcine and Ovine Derived Defibrotide: Coagulation Profiles, Molecular Characteristics, and DNA Content.
Article in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundDefibrotide is a DNA-derived polyelectrolyte with anti-ischemic and antithrombotic effects, primarily used in post-bone marrow transplantation (BMT) veno-occlusive disease (VOD). Currently, it is produced from porcine mucosal tissue, which presents cultural, economic, and supply limitations.AimThis study compared coagulation activity, molecular profiles, and DNA content of porcine- versus ovine-derived defibrotide.MethodsActive pharmaceutical ingredient (API) samples of 19 porcine and 9 ovine defibrotide batches were dissolved in saline (1 mg/mL) and added to pooled plasma and whole blood (100 µg/mL). Coagulation was assessed using activated partial thromboplastin time (aPTT) and thrombin time (TT). Anti-Xa and anti-IIa activities were measured by amidolytic assays. DNA content was quantified via the heparin red method, and molecular weight was determined by size exclusion chromatography.ResultsNeither porcine nor ovine preparations showed anticoagulant effects in aPTT. Both produced mild, comparable anticoagulant activity in TT. Anti-Xa and anti-IIa values were similar across sources. Molecular weight profiles were also comparable (ovine: 16.8 ± 0.24 kDa vs porcine: 18.02 ± 0.32 kDa). DNA content showed no significant difference (ovine: 75.78 μg vs porcine: 79 μg/10 μg API).ConclusionOvine- and porcine-derived defibrotide demonstrated equivalent coagulation, molecular, and DNA content profiles. These findings suggest ovine mucosa is a viable alternative source for defibrotide, potentially improving accessibility, reducing cost, and addressing dietary restrictions associated with porcine-derived products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.